CVRx Added to Russell 2000® and 3000® Indexes
September 17, 2021 08:00 ET
|
CVRx, Inc.
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
Heart Failure POC and LOC Devices Market Worth USD 175.35 Million by 2027 at 16.2% - Report by Market Research Future (MRFR)
August 19, 2021 12:00 ET
|
Market Research Future
New York, US, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heart Failure POC & LOC Devices Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Heart...
CVRx Reports Second Quarter 2021 Financial and Operating Results
August 04, 2021 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference
July 29, 2021 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
July 28, 2021 08:00 ET
|
ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
July 21, 2021 17:28 ET
|
CVRx, Inc.
MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors
July 12, 2021 08:00 ET
|
CVRx, Inc.
MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 02, 2021 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx, Inc. Announces Upsized Pricing of Initial Public Offering
June 29, 2021 20:17 ET
|
CVRx, Inc.
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
June 10, 2021 11:19 ET
|
CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...